The main innovative changes in the ICC-defined MDS include the reclassification of MDS with blasts of 10–19% as MDS/AML, and the introduction of novel molecular-defining categories, including myeloid neoplasms with mutated TP53, and MDS/AML with MDS-related gene mutations. The gene discussed is TP53; the disease is myeloid neoplasm.